The association between serum activin A levels and albuminuria among community-dwelling middle-aged and older adults in Taiwan

Shih-Chen Chang1,5,13, Chien-Yi Hsu2,3,4,9,13, Li-Kuo Liu8,10, Ya-Wen Lu5,11, Yi-Lin Tsai5,11, Ruey-Hsing Chou5,6,9,11, Po-Hsun Huang5,6,9,11, Liang-Kung Chen8,10,12 & Shing-Jong Lin2,4,7,9,11,13

Activin A, a cytokine belonging to the transforming growth factor-β family, has been shown to play pivotal roles in tissue remodeling after renal injury and is present in elevated levels in diabetic patients. However, the association between activin A and albuminuria remains unclear. We aimed to evaluate their association by using cross-sectional data from community-dwelling middle-aged and older adults in Taiwan. We assessed 466 participants (67% male; mean age 71 ± 13 years) from the I-Lan Longitudinal Aging study for whom data pertaining to serum activin A level and urine albumin-to-creatinine ratio (UACR) were available. Of these, 323 (69%) had normal albuminuria, 123 (26%) had microalbuminuria, and 20 (4%) had overt albuminuria. Patients with overt albuminuria and microalbuminuria had significantly higher activin A concentrations than those in the normal albuminuria group (p < 0.001). Circulating activin A was significantly correlated with multiple risk factors, including higher systolic blood pressure and higher UACR. Univariate and multivariate results indicated that activin A level was an independent variable for albuminuria. The cutoff value of 602 pg/mL of activin A demonstrated a sensitivity of 70.6% and specificity of 75.7% (AUC 0.774) in diagnosing overt albuminuria. In conclusion, middle-aged and older adults with elevated activin A levels were associated with a higher incidence of albuminuria.

Albuminuria, a major presentation of chronic kidney disease caused by the deterioration of glomerular filtration function and increased excretion of albumin, has become a worldwide public health issue. Although it is a known predictor of poor renal function and is associated with all-cause mortality, the underlying mechanism of inflammatory cytokines in albumin secretion remains unclear. Clinically, traditional renal protection strategies, such as systolic pressure control and inflammation control, have been employed. However, recent studies have provided evidence that glomerular integrity gets irreversibly disrupted even before the development of albuminuria. As albuminuria a risk factor, prognostic marker, and therapeutic target for renal disease progression, it
Serum activin A level is associated with the extent of albuminuria. Inflammaging has been reported to be the dominant physiological change in older populations. The role of activin A in the cytokine spectrum of inflammation and kidney pathophysiology remains unclear. Thus, in our study, participants’ basic demographic, clinical characteristics, and serum activin A levels were surveyed (Table 1). A total of 466 participants from the ILAS study were eligible for this study. Among them, 323 (69.3%) had normal albuminuria, 123 (26%) had microalbuminuria, and 20 (4%) had overt albuminuria (Table 1). Participants with microalbuminuria and overt albuminuria were older and more likely to be diagnosed with diabetes mellitus, high systolic blood pressure (SBP), higher body mass index, higher urine albumin to creatinine ratios (UACRs), higher serum triglyceride levels, higher uric acid levels, higher HbA1c, and higher activin A levels. However, they had significantly lower total and high-density lipoprotein cholesterol levels and glomerular filtration rates (GFRs) than subjects with normal albuminuria (all p < 0.01). Similar to previous studies, most of these factors, including systolic blood pressure and renal function, are highly associated with human aging. Interestingly, activin A, an age-associated parameter in our study, was specifically associated with the different severities of albuminuria and overt albuminuria.

As seen in Fig. 1, subsequent analysis using ANOVA further justified that the significant increase (p < 0.001) in serum activin A level was associated with the elevated extent of albuminuria. This finding supports our hypothesis that increased circulating activin A level may directly or indirectly alter the integrity of glomerular function, causing albumin leakage. As shown in Fig. 2, SBP, eGFR, logUACR, and age were also significantly correlated with elevated activin A levels (p < 0.001).

Statistical evidence showed that elevated activin A was independently associated with albuminuria. Although hypertension plays a significant role in the development of albuminuria, the activin A-driven disturbance of glomerular function has been found by a previous study to play an equally significant role. In Table 2, we utilized logUACR, a more sophisticated parameter, to normalize albuminuria, and the univariate and multivariate analyses results indicated an association between elevated activin A and logUACR. The results presented in Table 2 further confirm the prior findings (Fig. 1 and Table 1) that elevated circulating activin A was positively associated with albuminuria. Table 3 summarizes the results of the univariate and multivariate logistic regression analyses, which showed that SBP (p < 0.001 in both analyses) and activin A levels were significantly associated with albuminuria (p < 0.001 in the univariate analysis, p < 0.012 in the multivariate analysis).
### Table 1. Comparison of general characteristics among the different albuminuria status.

*Values are mean ± SD or n (%); ALT, aminotransferase; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-estimated insulin resistance; IGF-1, insulin-like growth factor-1; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; UACR, urine albumin-to-creatinine ratio.

| Characteristic                        | Normal albuminuria (n = 323) | Microalbuminuria (n = 123) | Overt albuminuria (n = 20) | p value  | p trend |
|--------------------------------------|------------------------------|-----------------------------|-----------------------------|-----------|---------|
| Age, years                           | 67.6 ± 8.8                   | 71.9 ± 8.7                  | 73.5 ± 11.1                 | < 0.001** | 0.004*  |
| Sex, men                             | 161 (50)                     | 61 (50)                     | 11 (55)                     | 0.900     | 0.656   |
| BMI, kg                              | 24.4 ± 3.2                   | 25.3 ± 4.3                  | 26.2 ± 4.4                  | 0.009*    | 0.031*  |
| Waist circumference, cm              | 85.3 ± 9.1                   | 87.5 ± 10.2                 | 90.0 ± 11.1                 | 0.020*    | 0.036*  |
| Appendicular skeletal muscle mass, kg| 17.7 ± 4.1                   | 17.5 ± 3.5                  | 18.1 ± 3.8                  | 0.746     | 0.650   |
| Mini-Nutrition Assessment            | 27.0 ± 2.0                   | 26.9 ± 2.0                  | 26.7 ± 2.2                  | 0.808     | 0.556   |
| Current smoking                      | 61 (19)                      | 33 (27)                     | 1 (5)                       | 0.039*    | 0.134   |
| Hypertension                         | 148 (46)                     | 70 (57)                     | 16 (80)                     | 0.003*    | 0.003*  |
| Diabetes                             | 49 (15)                      | 32 (26)                     | 7 (35)                      | 0.006*    | 0.027*  |
| CAD                                  | 11 (3)                       | 5 (4)                       | 3 (15)                      | 0.039*    | 0.011*  |
| SBP, mmHg                            | 131.4 ± 15.0                 | 142.2 ± 18.7                | 145.9 ± 23.4                | < 0.001** | < 0.001**|
| Fasting glucose, mg/dL               | 99.6 ± 25.3                  | 107.5 ± 36.2                | 120.9 ± 51.3                | 0.001**   | 0.003*  |
| eGFR, ml/min                         | 75.2 ± 22.7                  | 69.1 ± 26.8                 | 56.1 ± 27.0                 | < 0.001** | 0.001**  |
| ALT, U/L                             | 28.1 ± 22.6                  | 28.6 ± 20.5                 | 28.6 ± 11.3                 | 0.973     | 0.927   |
| Total cholesterol, mg/dL             | 193.7 ± 33.4                 | 190.4 ± 38.3                | 187.6 ± 38.5                | 0.536     | 0.448   |
| HDL-C, mg/dL                         | 54.0 ± 13.4                  | 51.1 ± 11.7                 | 48.5 ± 12.9                 | 0.029*    | 0.064   |
| LDL-C, mg/dL                         | 120.9 ± 33.7                 | 119.3 ± 36.5                | 110.3 ± 40.1                | 0.398     | 0.183   |
| Triglyceride, mg/dL                  | 122.7 ± 96.3                 | 133.3 ± 108.6               | 215.7 ± 419.9               | 0.008*    | 0.002*  |
| Uric acid, mg/dL                     | 5.9 ± 1.4                    | 5.9 ± 1.5                   | 6.4 ± 1.3                   | 0.346     | 0.146   |
| Homocystein, µmol/L                  | 13.9 ± 7.1                   | 15.2 ± 5.8                  | 16.2 ± 5.4                  | 0.071     | 0.134   |
| hs-CRP, mg/L                         | 1.9 ± 3.5                    | 2.8 ± 4.3                   | 2.4 ± 3.4                   | 0.064     | 0.523   |
| Activin A, pg/mL                     | 503.6 ± 160.5                | 579.9 ± 193.2               | 665.9 ± 151.1               | < 0.001** | < 0.001**|
| Follistatin, pg/mL                   | 1587 ± 1372.5                | 1698.8 ± 620.3              | 2116.9 ± 990.8              | 0.133     | 0.057   |
| IGF-1, ng/mL                         | 123.1 ± 56.0                 | 117.2 ± 43.1                | 108.1 ± 36.2                | 0.316     | 0.225   |
| HOMA-IR,unit                         | 1.9 ± 1.6                    | 2.5 ± 2.8                   | 9.5 ± 25.3                  | < 0.001** | < 0.001**|
| UACR, mg/g                           | 8.4 ± 4.6                    | 52.8 ± 39.1                 | 914.9 ± 660.9               | < 0.001** | < 0.001**|

Figure 1. Serum activin A elevation is positively correlated to the severity of albuminuria.
Figure 2. The elevations in circulating activin A levels are correlated to the aging-related demographic parameters.

| Variable                                      | Univariate analysis | Multivariate analysis†    |
|-----------------------------------------------|---------------------|--------------------------|
|                                              | Coefficient | p value | Coefficient | p value |
| Age, years                                   | 0.248       | <0.001** | 0.289       | 0.068   |
| Sex, men                                      | 0.048       | 0.306    |             |         |
| Body mass index                               | 0.113       | 0.015*   | 0.125       | 0.970   |
| Waist circumference, cm                       | 0.096       | 0.015*   | −0.093      | 0.173   |
| Current smoking                               | 0.023       | 0.620    |             |         |
| Use of antihypertensive drug                  | 0.115       | 0.013*   | 0.038       | 0.413   |
| Systolic blood pressure, mmHg                 | 0.328       | <0.001** | 0.273       | <0.001**|
| Fasting plasma glucose, mg/dL                 | 0.170       | <0.001** | 0.106       | 0.031*  |
| Estimated glomerular filtration rate, mL/min/1.73 m² | −0.224      | <0.001** | −0.198      | 0.008*  |
| HDL-cholesterol, mg/dL                        | −0.065      | 0.162    |             |         |
| Triglycerides, mg/dL                          | 0.103       | 0.026*   | −0.019      | 0.757   |
| Homocysteine, μmol/L                          | 0.117       | 0.012*   | −0.017      | 0.732   |
| High-sensitivity C-reactive protein, mg/L     | 0.032       | 0.508    |             |         |
| Activin A, pg/mL                              | 0.256       | <0.001** | 0.122       | 0.012*  |
| Follistatin, pg/mL                            | 0.064       | 0.169    |             |         |
| HOMA-IR, unit                                 | 0.166       | <0.001** | 0.121       | 0.066   |

Table 2. Univariable and multivariable associations with log urine albumin-to-creatinine ratio (LogUACR). *p < 0.05, **p < 0.001. †The multivariate regression model included all available variables with a p-value < 0.100. eGFR estimated glomerular filtration rate, hs-CRP high-sensitivity C-reactive protein.
Serum activin A level is a positive predictor of albuminuria. Subsequently, we tested whether activin A could be a feasible and accurate predictor of albuminuria in clinical practice through a receiver operating characteristic (ROC) analysis (Fig. 3). Using the maximal Youden index, the optimal cutoff point of activin A level in the albuminuria group was determined to be at 490 pg/mL (sensitivity 74%, specificity 56.5%), with an area under the curve (AUC) of 0.673. Using the similar method, the optimal cutoff point in the overt albuminuria group was set at 602 pg/mL (sensitivity, 70.6%; specificity, 75.7%), with an AUC of 0.774.

Table 3. Logistic regression analysis of risk factors associated with microalbuminuria and overt albuminuria. *p < 0.05, **p < 0.001. CRP C-reactive protein, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment-estimated insulin resistance.
Discussion

The prevalence of chronic kidney disease has been increasing due to the increasing age of the population. Thus, a comprehensive and predictive marker is required. To date, the association between glomerular function integrity and albuminuria has been well established. However, the deterioration of albuminuria was considered under the progressive loss of renal function, caused by a bundle of mechanisms either in a string or in parallel. Microalbuminuria, ranging from 30 to 300 mg/day of urine albumin, is prevalent in patients with hypertension, diabetes, and renal disease. It is also present in healthy individuals. Our study tested the association, sensitivity, and specificity of circulating activin A with the various severities of albuminuria. Consistently, in a murine model, the elevation of activin A was associated with both aging and biomechanical cardiac stress. Activin A activation through the activin type II receptor induces the ubiquitin pathway, leading to the degradation of sarcoplasmic reticulum Ca\(^{2+}\) ATPase and loss of myocyte function. Our data show that activin A could be an early indicator for the prescription of cardiorenal-protective regimens. To the best of our knowledge, this study was the first to reveal an association between serum activin A and albuminuria. Interestingly, we found that increased activin A levels were associated with decreased GFRs and elevated albuminuria levels. Moreover, the multivariate analysis indicated that, similar to hypertension, which is a significant cause of albuminuria, increased activin A levels were also linked to micro- and macroalbuminuria.

In this study, we demonstrated that elevated activin A level was an independent risk factor for albuminuria. In our previous study, elevated activin A was associated with SBP and pulse pressure. To date, a basic study has proven that activin A can regulate blood pressure through the renin–angiotensin system. Therefore, we could infer from the previous study’s findings that activin A could cause albuminuria by up-regulating the SBP and pulse pressure, though there is lacking direct evidence on its underlying mechanism. Altogether, this study revealed the significance of serum activin A, which is directly or indirectly associated with albuminuria.

Our recent study also reported that elevated activin A was associated with pre-diabetic and diabetic patients. The progression of diabetes may be driven by a chronic onset systemic disease and predisposing factors, including altered metabolic and chronic inflammation. Diabetic retinopathy and diabetic renal disease, proven to be involved in vessel remodeling and endothelial cell injury, are the two most common diseases that manifest early in diabetic patients. Glucose itself is not the only factor leading to tissue remodeling as other inflammatory factors, such as the TGF-β superfamily, may also be implicated. Thus, in a previous study, we provided evidence that elevated serum activin A levels were associated with carotid intima-media thickness, showing that activin A was a crucial predisposing factor in the disruption vessel morphology integrity among diabetic patients. This idea and conclusion could be extended to this study since elevated activin A was significantly associated with albuminuria. Based on the evidence that activin A disrupts vessel morphology, we proposed that the renal artery and afferent arterioles were also affected to a certain extent, accompanied by endothelial cell dysfunction, resulting in albuminuria in patients with elevated activin A levels. Although whether activin A alters the renal vascular system’s homeostasis and the underlying mechanism governing association between serum activin A levels and albuminuria remain unclear, we concluded that systemic elevated activin A should be a positive associated risk factor for albuminuria.

In this study, the cutoff point of 490 pg/mL for the circulating activin A in the albuminuria group yielded a sensitivity of 74% and a specificity of 56.5%. Meanwhile, the cutoff point of 602 pg/mL in the overt albuminuria group lead to a sensitivity of 70.6% and specificity of 75.7%. The causal mechanism of activin A-driven albuminuria is complicated. The structural and functional integrity of the trinity of the glomerular infiltration structure, including endothelial cells, podocytes, and glomerular basement membranes, is directly associated with albuminuria. In this study, we dissected the link between activin A and the integrity of the glomerular infiltration structure layer by layer. First, as mentioned in previous studies, albuminuria is associated with systemic endothelial cell dysfunction. A recent cross-sectional, population-based study reported an association between albuminuria and reduced capillary density through skin capillaroscopy. Moreover, a recent study indicated a positive association between activin A and hypertension and suggested that in the scenario of a chronic disease progression, endothelial cell dysfunction was caused by multiple mechanisms. The lining of endothelial cells in the glomerular infiltration structure limits the passage of albumin. Thus, any interruptions in this delicate lining may amplify the level of albuminuria. Activin A has also been reported to induce endothelial cell dysfunction, contributing to the imbalance of endothelial-podocyte crosstalk, a major cause of albuminuria. Second, although activin A is essential for the differentiation of human stem cells into podocytes, a chronically elevated level of the pro-inflammatory type potentiates fibroblast activation, replacing injured cells with fibrosis deposition. Immunological stresses driven by circulating pro-inflammatory cytokines are the predominant causes of podocyte and endothelial cell dysfunction. Activin A, which has pro-inflammatory and pro-fibrotic properties, has also been found to play pivotal roles in chronic inflammation and tissue fibrosis, such as pulmonary, liver, and interstitial renal fibrosis. As a member of the TGF-β superfamily, activin A shares similar properties with TGF-β, which plays a substantial role in glomerular sclerosis and podocyte dysfunction through the activation of the TGF-β receptors on podocytes and endothelial cells. As such, cytokines related to the TGF-β superfamily may also cause podocyte and endothelial cell dysfunction. However, no human study has discovered the relationship between activin A levels and albuminuria. Although our study highlights that activin A could have a role in interrupting the integrity of glomerular filtration, leading to albuminuria, further translational studies are needed to establish its mechanism.

In the progression of renal function loss, acute renal injury, chronic inflammation, and tissue repair affect the overall outcome. As observed in a senescence study, TGF-β has been reported to trigger senescence cells to express p21 and p16, leading to cell cycle arrest. As a member of the TGF-β superfamily, activin A has also been reported to be part of the senescence secretome. Systemically elevated activin A may contribute to the senescence of renal tubular epithelial cells. Post-cell injury Senescence is a natural mechanism for immune response. In a murine model, it has been identified that TGF-β promotes senescence via the activation of the p53/p21 pathway. Therefore, it is reasonable to assume that activin A may also serve a similar role in the progression of renal injury, thus contributing to albuminuria. As a member of the TGF-β superfamily, activin A could be considered a positive associated risk factor for albuminuria. In conclusion, we hypothesized that elevated activin A was associated with decreases in GFRs and elevated albuminuria levels. Moreover, further translational studies are needed to establish the mechanism.
surveillance and prevention of tumor cell generation. During phase senescence, cells implement a complicated pro-inflammatory response, termed the senescence-associated secretory phenotype (SASP)\textsuperscript{33}. The secretome of senescence is the most important signal in the activation of immune responses. In a recent study, activin A was also reported to play a role in paracrine senescence. On the other hand, in acute kidney injury, a recent study indicated that activin A, which is primarily secreted by the proximal tubular cell, is associated with tissue injury and tissue repair inhibition. Tubular cell injury was expected to impair the endocytic filtration of albumin, resulting in the worsening of albuminuria. In summary, our study showed that activin A elevation linked to albuminuria might be a chronic outcome driven by renal tubular epithelial senescence\textsuperscript{32–34}.

Though the mechanism by which activin A drives albuminuria remains unclear, tissue injury and inflammation mechanisms may play crucial roles in this process. To the best of our knowledge, the present study is the first to disclose the association between albuminuria and serum activin A levels. In this study, we found that increased activin A levels were related to albuminuria, similar to hypertension.

In conclusion, middle-aged and older adults with elevated activin A levels were associated with a higher incidence of microalbuminuria/overt albuminuria, independent of hypertension or diabetes. Circulating activin A levels might be a positive associated factor of albuminuria. Further studies are warranted to assess the causal relationships and clinical relevance.

Material and methods

Study population. The I-Lan Longitudinal Aging study (ILAS) is a community-based cohort study for the middle-aged and older adults in I-Lan County of Taiwan. This study was approved by the institutional review board of the National Yang Ming University (approval no. YM103008). The ILAS study aimed to evaluate the complex associations between age and multiple factors, including hormones, comorbidities, sarcopenia, and cognitive function. A random selection of community-dwelling adults above 50 years of age in I-Lan County, Taiwan was performed in this study. The exclusion criteria were: (i) inhabitants who were unable to communicate with the research nurse or grant an interview; (ii) inhabitants who were unable to complete the evaluation tests due to poor functional status; (iii) inhabitants who had limited life expectancy (<6 months) due to major illnesses; and (iv) current residents of long-term care facilities. We conducted our study in compliance with the recognized international standards, including the principles of the Declaration of Helsinki. All participants had given their written informed consents, and the study was approved by the Institutional Review Board (IRB) of the National Yang-Ming University, Taipei, Taiwan (IRB: YM103008).

Demography, physical examination, and laboratory examination. The patients’ medical history including events of chronic renal diseases, cardiovascular diseases, and cerebrovascular diseases, and risk factors were documented through a personal interview. Weight, height, and waist circumference were measured, and the body mass index was calculated. Brachial blood pressure was assessed with a sphygmomanometer after patients had been sitting for more than 15 min. The average of three SBP measurements was used for analysis in this study. All blood samples were drawn with the participant in a seated position after a 10-h overnight fast. Serum activin A levels were measured using an enzyme-linked immunosorbent assay. Serum concentrations of glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were determined using an automatic analyzer (ADVIA 1800, Siemens, Malvern, PA, USA). Whole-blood glycated hemoglobin A1c was measured by an enzymatic method using a Tosoh G8 HPLC Analyzer (Tosoh Bioscience, San Francisco, CA, USA). The serum levels of hs-CRP, homocysteine, and insulin-like growth factor-1 were also measured.

Measurement for urinary albumin excretion and definition of albuminuria. A single voided morning urine sample was used to measure the UACR (mg/g). UACR measured in a spot urine sample is highly correlated with 24-h urine albumin excretion. The presence of microalbuminuria is defined as a UACR of 30–300 mg/g. The presence of overt albuminuria is defined as a UACR >300 mg/g.

Statistical analysis. The analysis was performed on the complete data set, and the results are expressed as mean ± SD or percentage frequency. Analysis of variance (ANOVA) was used to compare the continuous variables among the three groups. Logistic regression analysis was performed to evaluate the association between the activin A levels and the various factors. A univariate and multivariate approach was used to analyze the association between the activin A levels and associated parameters. ROC analysis was also performed to evaluate the predictive accuracy of activin A in the diagnosis of microalbuminuria and overt albuminuria. Data were analyzed using the SPSS software (version 20, SPSS, Chicago, IL, USA). A p-value of <0.05 was considered to indicate statistical significance.

Received: 28 May 2021; Accepted: 13 September 2021
Published online: 08 October 2021

References

1. Allison, S. J. Nephrotic syndrome: Insights into protein scaffolds of the slit diaphragm. Nat. Rev. Nephrol. 12, 441. https://doi.org/10.1038/nrneph.2016.94 (2016).

2. Blaine, J. & Levi, M. Chronic kidney disease: Albuminuria or CKD stage as best marker of CVD in diabetes?. Nat. Rev. Nephrol. 8, 376–377. https://doi.org/10.1038/nrneph.2012.110 (2012).

3. Andrade, L., Rodrigues, C. E., Gomes, S. A. & Noronha, I. L. Acute kidney injury as a condition of renal senescence. Cell Transplant. 27, 739–753. https://doi.org/10.1177/0963689717743512 (2018).
4. Boor, P. Biomarkers: Albuminuria—A marker of systemic microvascular function. Nat. Rev. Nephrol. 12, 449–450. https://doi.org/10.1038/nrneph.2016.82 (2016).

5. Chang, A. R. & Appel, L. J. Target blood pressure for cardiovascular disease prevention in patients with CKD. Clin. J. Am. Soc. Nephrol. 13, 1572–1574. https://doi.org/10.2215/CJN.02132018 (2018).

6. Mallamaci, F. et al. ACE inhibition is renoprotective among obese patients with proteinuria. J. Am. Soc. Nephrol. 22, 1122–1128. https://doi.org/10.1681/ASN.2010090969 (2011).

7. Anderson, A. H. Screening for proteinuria: A tool for predicting rapid declines in kidney function?. J. Am. Soc. Nephrol. 22, 1580–1583. https://doi.org/10.1681/ASN.2011070730 (2011).

8. Fried, L. F. & Lewis, J. Albuminuria is not an appropriate therapeutic target in patients with CKD: The con view. Clin. J. Am. Soc. Nephrol. 10, 1089–1093. https://doi.org/10.2215/CJN.10681014 (2015).

9. Lambers Heerspink, H. J. & Gansevoort, R. T. Albuminuria is an appropriate therapeutic target in patients with CKD: The pro view. Clin. J. Am. Soc. Nephrol. 10, 1079–1088. https://doi.org/10.2215/CJN.11511114 (2015).

10. Boor, P., Ostendorf, T. & Floege, J. Renal fibrosis: Novel insights into mechanisms and therapeutic targets. Nat. Rev. Nephrol. 6, 643–656. https://doi.org/10.1038/nrneph.2010.120 (2010).

11. Catrân, D. C. Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy?. J. Am. Soc. Nephrol. 18, 1633–1634. https://doi.org/10.1681/ASN.2007040433 (2007).

12. Flyvbjerg, A. The role of the complement system in diabetic nephropathy. Nat. Rev. Nephrol. 13, 311–318. https://doi.org/10.1038/nrneph.2017.31 (2017).

13. Leonard, W. N. et al. Inhibition of activin signaling slows progression of polycystic kidney disease. J. Am. Soc. Nephrol. 27, 3589–3599. https://doi.org/10.1681/ASN.2015030287 (2016).

14. Nordholm, A. et al. Klotho and activin A in kidney injury: Plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney. Am. J. Physiol. Renal Physiol. 314, F753–F762. https://doi.org/10.1152/ajprenal.00528.2017 (2018).

15. Sugatani, T. Systemic activation of activin A signaling causes chronic kidney disease-mineral bone disorder. Int. J. Mol. Sci. https://doi.org/10.3390/ijms19092490 (2018).

16. Franceschi, C., Garagnani, P., Parini, P., Giulian, C. & Santoro, A. Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576–590. https://doi.org/10.1038/nrendo.2018.85 (2018).

17. Bian, X. et al. Senescence marker activin A is increased in human diabetic kidney disease: Association with kidney function and potential implications for therapy. BMJ Open Diabetes Res. Care 7, e000720. https://doi.org/10.1136/bmjdrc-2019-000720 (2019).

18. Abbate, M., Zoja, C. & Remuzzi, G. How does proteinuria cause progressive renal damage?. J. Am. Soc. Nephrol. 17, 2974–2984. https://doi.org/10.1681/ASN.2006040377 (2006).

19. Sayantlooran, S., Magana-Arachchi, D. N., Gunerathne, L. & Abeysekera, T. Potential diagnostic biomarkers for chronic kidney disease of unknown etiology (CKDus) in Sri Lanka: A pilot study. BMC Nephrol. 18, 31. https://doi.org/10.1186/s12882-017-0440-x (2017).

20. Roh, J. D. et al. Activin type II receptor signaling in cardiac aging and heart failure. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aau6680 (2019).

21. Tzai, Y. L. et al. The association between serum activin A levels and hypertension in the elderly: A cross-sectional analysis from I-Lan Longitudinal Aging Study. J. Hypertens. 31, 369–374. https://doi.org/10.1093/jhj/hbx185 (2018).

22. Takahashi, H., Yoshika, M., Komiya, Y. & Nishimura, M. The central mechanism underlying hypertension: A review of the roles of sodium ions, epithelial sodium channels, the renin–angiotensin–aldosterone system, oxidative stress and endogenous digitalis in the brain. Hypertens. Res. 34, 1147–1160. https://doi.org/10.1038/hr.2011.105 (2011).

23. Kuo, C. S. et al. Increased activin A levels in prediabetes and association with carotid intima-media thickness: A cross-sectional analysis from I-Lan Longitudinal Aging Study. Sci. Rep. 8, 9957. https://doi.org/10.1038/s41598-018-27795-2 (2018).

24. Martens, R. J. et al. Capillary rarefaction associates with albuminuria: The Maastricht Study. J. Am. Soc. Nephrol. 27, 3748–3757. https://doi.org/10.1681/ASN.2015111219 (2016).

25. Brinkloetter, P. T., Ising, C. & Benzing, T. The role of the podocyte in albumin filtration. Nat. Rev. Nephrol. 9, 328–336. https://doi.org/10.1038/nrneph.2013.78 (2013).

26. Carney, E. F. Podocytes: ShcA regulates nephrin turnover. Nat. Rev. Nephrol. 13, 722. https://doi.org/10.1038/nrneph.2017.153 (2017).

27. Petred, A. et al. Proteinuria impairs podocyte regeneration by sequestering retinoic acid. J. Am. Soc. Nephrol. 24, 1756–1768. https://doi.org/10.1681/ASN.2012090950 (2013).

28. Schüffer, M. et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J. Clin. Investig. 108, 807–816. https://doi.org/10.1172/JCI12367 (2001).

29. Shankland, S. I. The podocyte’s response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int. 69, 2131–2147. https://doi.org/10.1038/sj.ki.5004010 (2006).

30. Siddiqui, F. S. & Advani, A. Endothelial-podocyte crosstalk: The missing link between endothelial dysfunction and albuminuria in diabetes. Diabetes 62, 3647–3655. https://doi.org/10.2337/db13-0795 (2013).

31. Schmitt, R. & Melk, M. Molecular mechanisms of renal aging. Kidney Int. 92, 569–579. https://doi.org/10.1016/j.kint.2017.02.036 (2017).

32. Acosta, J. C. et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978–980. https://doi.org/10.1038/ncb2784 (2013).

33. Ito, Y., Hoare, M. & Narita, M. Spatial and temporal control of senescence. Trends Cell Biol. 27, 820–832. https://doi.org/10.1016/j.tcb.2017.07.004 (2017).

34. Schmitt, R., Susnik, N. & Melk, M. Cellular aspects of renal senescence. Curr. Opin. Organ Transplant. 20, 412–416. https://doi.org/10.1097/MOT.00000000000000214 (2015).

35. Lin, Y. Y. & Huang, C. S. Aging in Taiwan: Building a society for active aging and aging in place. Gerontologist 56(2), 176–183. https://doi.org/10.1093/geront/gnv017 (2016).

36. Hwang, S. I., Tsai, J. C. & Chen, H. C. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton) 15(Suppl 2), 3–9 (2010).

37. Kuo, H. W., Tsai, S. S., Tiao, M. M. & Yang, C. Y. Epidemiological features of CKD in Taiwan. J. Kidney Dis. 49, 46–55 (2007).

38. Hill, N. R. et al. Global prevalence of chronic kidney disease—A systematic review and meta-analysis. PLoS One 11(7), e0158765. https://doi.org/10.1371/journal.pone.0158765 (2016).
of Science and Technology (MOST-106-2314-B-002-173-MY3, MOHW 106-TDU-B-211-113001, MOST-110-2314-B-038-131). The funding institutions took no part in the study design, data collection or analysis, publication intent, or manuscript preparation.

**Author contributions**
Research idea and study design: C-YH, Y-LT; data acquisition: L-KL, Y-WL, L-KC; data analysis/interpretation: S-CC, C-YH; statistical analysis: C-YH, R-HC; drafted the manuscript: S-CC, C-YH, P-HH; supervision or mentorship: P-HH, S-JL. All authors reviewed the manuscript. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. P-HH and S-JL take responsibility that this study has been reported honestly, accurately, and transparently.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to P.-H.H. or S.-J.L.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access] This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2021